NCT05047822 (RAVEN) is a clinical trial in Covid-19 Infection, sponsored by AstraZeneca.

Who is sponsoring NCT05047822?

NCT05047822 is sponsored by AstraZeneca.

What condition does NCT05047822 study?

NCT05047822 studies Covid-19 Infection.

Is NCT05047822 still recruiting?

NCT05047822 is currently completed. Last updated 18 November 2023.

Last reviewed 2023-11-18 · How we verify

NCT05047822: RAVEN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oxford/AstraZeneca COVID-19 Vaccine Effectiveness in England

Completed Last updated 18 November 2023

What this trial tests

trial in Covid-19 Infection in 18,373,714 participants. Completed in 27 January 2023.

Timeline

23 August 2021

Primary endpoint
27 January 2023

27 January 2023

Quick facts

Lead sponsor	AstraZeneca
Status	Completed
Study type	OBSERVATIONAL
Enrollment	18,373,714
Start date	23 August 2021
Primary completion	27 January 2023
Estimated completion	27 January 2023
Sites	1 location across United Kingdom

Conditions studied

Covid-19 Infection — all drugs for Covid-19 Infection →

Sponsor

AstraZeneca — full company profile →

Who can join

12 and older, any sex, with Covid-19 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a retrospective cohort study to assess the real world effectiveness of the Oxford/AstraZeneca COVID-19 vaccine in England. The study is using linkage of the English national databases on COVID-19 vaccination, testing, medical records, hospitalization, and death.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty: The RAVEN cohort study.
Meeraus W, Joy M, Ouwens M, Taylor KS, et al · · 2024 · cited 9× · PMID 38431156 · DOI 10.1016/j.jinf.2024.106129
Correcting for the Inflated Adult Population Denominator in an English Nationwide Health Care Cohort: Database Analysis Study.
Venkatesan S, Joy M, Jamie G, Kar D, et al · · 2025 · PMID 41144579 · DOI 10.2196/64788
Features influencing the health and economic impact of preventing COVID-19 in immunocompromised individuals.
Chen S, Venkatesan S, Arnetorp S, Bergenheim K, et al · · 2025 · PMID 40455922 · DOI 10.1371/journal.pcbi.1013072

Verify or expand the search:

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05047822 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 18 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05047822.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing